期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

肿瘤分子靶点检测的方法学 被引量：2

原文传递
导出
摘要 随着生物技术在肿瘤研究领域的快速发展和从细胞分子水平对发病机制的深入认识，肿瘤治疗已进入了一个全新的靶向时代。由于靶向治疗药物是依据肿瘤发生发展中已知的异常分子或基因设计和研制的，然而并非所有患者均存在药物作用靶点，即使存在药物靶点，其异常状况亦不完全相同，药物的治疗效果也存在差异。
作者 王建飞 石远凯 韩晓红
机构地区 北京协和医学院中国医学科学院肿瘤医院内科
出处 《中华检验医学杂志》 CAS CSCD 北大核心 2012年第5期478-480,共3页 Chinese Journal of Laboratory Medicine
基金 国家高技术研究发展计划（863计划）资助项目（2011AA02A110） 国家重大新药创制科技重大专项资助项目（2012ZX09303012） 卫生部医药卫生科技发展基金资助项目（200902002-1）
关键词 肿瘤分子靶点 检测 方法学 治疗 药物
分类号 R730.4 [医药卫生—肿瘤]
  • 相关文献

参考文献15

  • 1Whitehall V, Tran K, Umapathy A, et al. A multicenter blinded study to evaluate KRAS mutation testing methodologies in the clinical setting. J Mol Diagn, 2009,11:543-552.
  • 2Franklin WA, Haney J, Sugita M, et al. KRAS mutation : comparison of testing methods and tissue sampling techniques in colon cancer. J Mol Diagn, 2010,12:43-50.
  • 3Han HS, Lim SN, An JY, et al. Detection of EGFR mutation status in lung adenocarcinoma specimens with different proportions of tumor cells using two methods of differentia[ sensitivity. J Thorac Oncol, 2012,7:355-364.
  • 4Song C, Milbury CA, Li J, et al. Rapid and sensitive detection of KRAS mutation after fast-COLD-PCR enrichment and high- resolution melting analysis. Diagn Mol Pathol, 2011,20:81-89.
  • 5Farifia Sarasqueta A, Moerland E, de Bruyne H, et al. SNaPshot and StripAssay as valuable alternatives to direct sequencing for KRAS mutation detection in colon cancer routine diagnostics. J Mol Diagn, 2011,13:199-205.
  • 6Kimura H, Fujiwara Y, Sone T, et al. High sensitivity detection of epidermal growth factor receptor mutations in the pleural effusion of non-small cell lung cancer patients. Cancer Sci, 2006,97:642- 648.
  • 7Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med, 2009,361:958-967.
  • 8Fassina A, Gazziero A, Zardo D, et al. Detection of EGFR and KRAS mutations on trans-thoracic needle aspiration of lung nodules by high resolution melting analysis. J Clin Pathol, 2009,62:1096-1102.
  • 9Zhou Q, Zhang XC, Chen ZH, et al. Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer. J Clin Oncol, 2011,29: 3316-3321.
  • 10Dowsett M, Bartlett J, Ellis IO, et al. Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres. J Pathol, 2003,199:418-423.

二级参考文献34

  • 1Yarden Y.Biology of HER-2 and its importance in breast cancer.Oncology,2001,61(Suppl 2):1-13.
  • 2Yarden Y,Sliwkowski MX.Untangling the ErbB signaling network.Nat Rev Mol Cell Biol,2001,2:127-137.
  • 3Ross JS,Fletcher JA,Linette GP,et al.The HER-2/neu gene and protein in breast cancer 2003:biomarker and target of therapy.Oncologist,2003,8:307-325.
  • 4Eccles SA.The role of c-erbB-2/HER-2/neu in breast cancer progression and metastasis.J Mammary Gland Biol Neoplasia,2001,6:393-406.
  • 5Mass R.The role of HER-2 expression in predicting response to therapy in breast cancer.Semin Oncol,2000,27(6 Suppl 11):46-52.
  • 6Zhang F,Yang Y,Smith T,et al.Correlation between HER-2 expression and response to neoadjuvant chemotherapy with 5-fluorouracil,doxorubicin,and cyclophosphamide in patients with breast carcinoma.Cancer,2003,97:1758-1765.
  • 7Sui W,Ou M,Chen J,et al.Comparison of immunohistochemistry (IHC) and fluorescence in situ hybridization(FISH) assessment for Her-2 status in breast cancer.World J Surg Oncol,2009,7:83.
  • 8Moliterni A,Menard S,Valagussa P,et al.HER-2 overexpression and doxorubicin in adjuvant chemotherapy for resectable breast cancer.J Clin Oncol,2003,21:458-462.
  • 9Vogel CL,Cobleigh MA,Tripathy D,et al.Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER-2-overexpressing metastatic breast cancer.J Clin Oncol,2002,20:719-726.
  • 10Romond EH,Perez EA,Bryant J,et al.Doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab as adjuvant therapy for patients with HER-2 positive operable breast cancer.N Engl J Med,2005,353:1673-1684.

共引文献19

同被引文献46

  • 1Conrads TP,Fusaro VA,Ross S,et al.High-resolution serum proteomic features for ovarian cancer detection.Endocr Relat Cancer,2004,11:163-178.
  • 2Cubedo J,Padró T,García-Moll X,et al.Proteomic signature of Apolipoprotein J in the early phase of new-onset myocardial infarction.J Prote Res,2011,10:211-220.
  • 3Mehan MR,Ayers D,Thirstrup D,et al.Protein signature of lung cancer tissues.PLoS One,2012,7:e35157.
  • 4Brown DL,Andreotti RF,Lee SI,et al.ACR appropriateness criteria.Ovarian cancer screening.Ultrasound Quarterly,2010,26:219-223.
  • 5Lorkova L,Pospisilova J,Lacheta J,et al.Decreased concentrations of retinol-binding protein 4 in sera of epithelial ovarian cancer patients:a potential biomarker identified by proteomics.Oncology Reports,2012,27:318-324.
  • 6Clarke CH,Yip C,Badgwell D,et al.Proteomic biomarkers apolipoprotein Al,truncated transthyretin,and connective tissue activating protein Ⅲ enhance the sensitivity of CA125 for detecting early stage epithelial ovarian cancer.Gynecologic Oncology,2011,122:548-553.
  • 7Matsubara J,Honda K,Ono M,et al.Reduced plasma level of CXC chemokine ligand 7 in patients with pancreatic cancer.Cancer Epidemiol Biomarkers Prev,2011,20:160-171.
  • 8Pina F,Botelho F,Lopes T,et al.Can serum angiogenin be used to improve the diagnostic performance in prostate cancer screening? Eur J Cancer Prev,2013,in press.
  • 9Wang J,Wang X,Lin S,et al.Identification of kininogen-1 as a serum biomarker for the early detection of advanced colorectal adenoma and colorectal cancer.PloS One,2013,8:e70519.
  • 10Vincent M.Cancer:a de-repression of a default survival program common to all cells? A life-history perspective on the nature of cancer.Bioessays,2012,34:72-82.

引证文献2

二级引证文献12

中华检验医学杂志
2012年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部